Matthew Shawn Morris Sells 16,550 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVAGet Free Report) Director Matthew Shawn Morris sold 16,550 shares of the business’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $25.00, for a total transaction of $413,750.00. Following the completion of the sale, the director directly owned 68,188 shares in the company, valued at $1,704,700. This represents a 19.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Matthew Shawn Morris also recently made the following trade(s):

  • On Thursday, February 26th, Matthew Shawn Morris sold 7,788 shares of Privia Health Group stock. The shares were sold at an average price of $24.99, for a total value of $194,622.12.
  • On Friday, December 12th, Matthew Shawn Morris sold 13,647 shares of Privia Health Group stock. The shares were sold at an average price of $25.01, for a total transaction of $341,311.47.

Privia Health Group Price Performance

NASDAQ:PRVA traded up $0.29 on Monday, hitting $24.04. 1,472,614 shares of the company’s stock were exchanged, compared to its average volume of 813,700. The firm has a 50-day moving average price of $23.07 and a 200-day moving average price of $23.50. Privia Health Group, Inc. has a 52 week low of $18.77 and a 52 week high of $26.51. The company has a market cap of $2.96 billion, a P/E ratio of 141.41, a price-to-earnings-growth ratio of 1.59 and a beta of 0.82.

Privia Health Group (NASDAQ:PRVAGet Free Report) last released its earnings results on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.21. The business had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The firm’s revenue was up 17.4% on a year-over-year basis. During the same period last year, the business earned $0.21 earnings per share. On average, research analysts expect that Privia Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Institutional Trading of Privia Health Group

Several hedge funds have recently added to or reduced their stakes in the business. Great Lakes Advisors LLC bought a new stake in shares of Privia Health Group in the third quarter worth about $4,487,000. Advantage Alpha Capital Partners LP purchased a new stake in shares of Privia Health Group in the 2nd quarter worth about $3,941,000. Hsbc Holdings PLC increased its stake in shares of Privia Health Group by 69.2% in the 2nd quarter. Hsbc Holdings PLC now owns 113,718 shares of the company’s stock worth $2,549,000 after acquiring an additional 46,526 shares in the last quarter. Edgestream Partners L.P. bought a new position in shares of Privia Health Group in the 2nd quarter worth about $2,209,000. Finally, Bailard Inc. purchased a new position in Privia Health Group during the 2nd quarter valued at about $531,000. 94.48% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PRVA. Wolfe Research set a $31.00 price target on shares of Privia Health Group in a research report on Tuesday, January 6th. Canaccord Genuity Group lifted their target price on Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. JPMorgan Chase & Co. upped their price target on Privia Health Group from $32.00 to $33.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Evercore lifted their target price on Privia Health Group from $28.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, Royal Bank Of Canada assumed coverage on Privia Health Group in a research note on Friday, January 9th. They issued an “outperform” rating and a $31.00 price objective for the company. Thirteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.93.

View Our Latest Analysis on Privia Health Group

Privia Health Group Company Profile

(Get Free Report)

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.

Recommended Stories

Insider Buying and Selling by Quarter for Privia Health Group (NASDAQ:PRVA)

Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.